Abstract
A prospective longitudinal study was conducted to determine whether single-donor fresh frozen plasma (FFP) substitution was able to influence L-asparaginase-associated hypoproteinemia. Within a 36-month period, 20 of 42 children with ALL received a total of 42 prophylactic FFP doses at a median of 10 (5-20) mliter/kg when fibrinogen levels decreased to < 60 mg/dL and thrombin time was lengthened. Laboratory monitoring before, during and after FFP substitution showed no short-term improvements and demonstrated only a minimal increase in fibrinogen and alpha 2-antiplasmin. Plasma levels of antithrombin and plasminogen remained unchanged. Furthermore, administration of FFP had no influence on thrombin generation, the plasmin/alpha 2-antiplasmin complex or enhanced D-dimer formation.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Afibrinogenemia / chemically induced
-
Antifibrinolytic Agents*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Antithrombins / deficiency
-
Asparaginase / administration & dosage
-
Asparaginase / adverse effects*
-
Blood Coagulation Disorders / chemically induced*
-
Blood Coagulation Disorders / therapy*
-
Fibrin Fibrinogen Degradation Products / analysis
-
Fibrinolysin / analysis
-
Plasma*
-
Plasminogen / deficiency
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Protein C / analysis
-
Thrombin Time
-
Treatment Failure
-
alpha-2-Antiplasmin / analysis
Substances
-
Antifibrinolytic Agents
-
Antithrombins
-
Fibrin Fibrinogen Degradation Products
-
Protein C
-
alpha-2-Antiplasmin
-
plasmin-plasmin inhibitor complex
-
Plasminogen
-
Fibrinolysin
-
Asparaginase